Patient Satisfaction and Quality of Life Impact - PecFent® (Qualipec)
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.
• Study objectives include assessment of early treatment satisfaction.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)|
- Satisfaction [ Time Frame: Satisfaction will be assessed approximately 1 hour after each BTPc episode treated with PecFent® from completion of titration through Day 7 ] [ Designated as safety issue: No ]Satisfaction will be assessed using a 4-point Likert scale.
|Study Start Date:||September 2012|
|Estimated Primary Completion Date:||March 2014 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01693328
|Contact: Sylvie Allouche, MDfirstname.lastname@example.org|
|Contact: Jerome Fayette, MD +33487785451 email@example.com|
|Principal Investigator: Jerome Fayette, MD|
|Principal Investigator:||Alain Serrie, MD||Head of Pain Federation - Palliative Medicine Lariboisiere Hospital, Paris France|